Through case study, recognize appropriate patient types for FVIII replacement therapy, and the considerations in personalizing their regimens. Learn more about ADYNOVATE’s consistent safety profile, and the outcomes of the ADYNOVATE Real-world Study.

Update audience on the advances in plasma manufacturing, including COVID-19 information.
This presentation will review the plasma collection and manufacturing process, including all of the steps necessary to help ensure the safety of donated plasma. Discussion will also include the ongoing surveillance for emerging pathogens and commitment to safety to ensure high quality, plasma derived, coagulation factor.

Introduce HTCs, NHF Chapters and HFA Member Organizations to collaboration examples and ideas on better communication with one another to affect increased support system of services and offerings within the Bleeding Disorders community. Define connections and separations of Hemophilia Alliance, Hemophilia Alliance Foundation and The Alliance Pharmacy.

Join us for this interactive webinar focused on how managing patients with hemophilia A has evolved during these unprecedented times. Hear from our nurses, Maya and Jenn, as they have a candid discussion on their experiences adapting to telehealth and using virtual strategies to start patients on HEMLIBRA, a subcutaneous prophylactic therapy.

Join us as we discuss NEW published data from two extension studies, affirming long-lasting efficacy with up to 4 years of evaluating adult and adolescent patients treated prophylactically at both 7- and 14-day extended intervals.